Literature DB >> 10717107

Radiation Therapy for Esophageal Cancer: Improving the Therapeutic Ratio.

.   

Abstract

Recent studies in nonmetastatic cancer of the esophagus have shown improved local control and survival by the use of combined chemotherapy and radiation therapy compared with radiation only. This has been achieved by accepting an increased incidence of acute side effects, usually mucositis or myelosuppression, secondary to the concurrent therapy. Local tumor resistance or progression has been a major problem, occurring in approximately half of patients following chemoradiation. This article reviews alternative radiation therapy techniques that could allow dose intensification, thereby improving tumor control without causing unacceptable acute or chronic treatment complications, ie, improving the therapeutic ratio. Total dose escalation using brachytherapy, or conventional or altered fractionation are discussed. Improvements in radiation treatment planning, including patient positioning, modifications in normal tissues encompassed within the target volume, and three-dimensional treatment planning are potential methods of decreasing the normal tissue complications that should be explored.

Entities:  

Year:  1994        PMID: 10717107     DOI: 10.1053/SRAO00400192

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  2 in total

1.  High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer.

Authors:  B G Taal; B M Aleman; C C Koning; H Boot
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

2.  Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer.

Authors:  Ivan M Buzurovic; Jorgen L Hansen; Mandar S Bhagwat; Desmond A O'Farrell; Scott Friesen; Thomas C Harris; Antonio L Damato; Robert A Cormack; Neil E Martin; Phillip M Devlin
Journal:  J Contemp Brachytherapy       Date:  2016-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.